Vertex Pharmaceuticals Income Tax at U.S. Statutory Rate remained flat by 0.0% to $243.78M in Q4 2025 compared to the prior quarter.
Used as a benchmark to evaluate the effectiveness of the company's tax planning and the impact of various tax incentives.
The theoretical income tax expense calculated by applying the standard federal statutory tax rate to the company's pre-t...
Standard baseline metric in tax rate reconciliations for all public companies.
is_cat_income_tax_at_statutory_rate| FY'25 | |
|---|---|
| Value | $975.10M |
We use cookies for analytics. See our Privacy and Cookie Policy.